Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia

• Autor(a) principal: Bassi,Sarah Cristina
• Data de Publicação: 2012
• Outros Autores: Rego,Eduardo Magalhães
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000200013
• topic: leukemia, promyelocytic, acute/epidemilogy; leukemia, myeloid, acute/epidemiology; leukemia, promyelocytic, acute/diagnosis; leukemia, myeloid, acute/diagnosis; leukemia, promyelocytic, acute/drug therapy; leukemia, myeloid, acute/drug therapy

Acute promyelocytic leukemia is characterized by gene rearrangements that always involve the retinoic acid receptor alpha on chromosome 15. In the majority of patients t(15;17) is detected, which generates the promyelocytic leukemia gene/retinoic acid receptor alpha rearrangement. This rearrangement interacts with several proteins, including the native promyelocytic leukemia gene, thus causing its delocalization from the nuclear bodies, impairing its function. The immunofluorescence staining technique using the anti-PML antibody may be used to provide a rapid diagnosis and to immediately start therapy using all-trans retinoic acid. The experience of the International Consortium on Acute Promyelocytic Leukemia has demonstrated that early mortality was significantly reduced by adopting the immunofluorescence technique. All-trans retinoic acid combined with chemotherapy is the standard therapy; this promotes complete remission rates greater than 90% and cure rates of nearly 80%. However, early mortality is still an important limitation and hematologists must be aware of the importance of treating newly diagnosed acute promyelocytic leukemia as a medical emergency.